Adlai Nortye Biopharma Co., Ltd.   Report issue

For profit Phase 1 Phase 3
Founded: Hangzhou http://www.adlainortye.com/en_about.php China (2014)

Organization Overview

First Clinical Trial
2020
NCT04432857
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Adlai Nortye | Adlai Nortye Biopharma Co., Ltd. | Adlai Nortye USA Inc | ADLAI NORTYE USA INC. | Adlai Nortye US Inc

Active Ingredients

Drugs in Phase 3 Trials (2)

buparlisib (2 trials)

paclitaxel (taxol) (1 trial)

Drugs in Phase 1 Trials (5)

an0025 (4 trials)

an4005 (1 trial)

atezolizumab (Tecentriq) (1 trial)

pelareorep (1 trial)

pembrolizumab (keytruda) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Transitional Cell (Phase 1)

Head and Neck Neoplasms (Phase 3)

Triple Negative Breast Neoplasms (Phase 1)

Urinary Bladder Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 7